Prostate-Specific Expression of p53R172L Differentially Regulates p21, Bax, and mdm2 to Inhibit Prostate Cancer Progression and Prolong Survival11National Cancer Institute awards CA58206, CA64851, and CA884296 and a CaP CURE award to N. M. G.Note: Immaculada Hernandez, Lisette A. Madison and Yongli Wei contributed equally to this work.

2003 
Loss of heterozygosity or mutation at the p53 tumor suppressor gene locus is frequently associated with advanced human prostate cancer. Hence, replacement p53 gene therapy may prove to be efficacious for this disease. While many mutations result in p53 molecules with oncogenic properties, other variants may possess wild-type properties with increased tumor suppressor activity. We have chosen to investigate the activity of a naturally occurring variant p53 molecule, p53 R172L , carrying an arginine-to-leucine mutation at codon 172. We demonstrate that p53 R172L can differentially activate expression of genes involved in cell cycle control and apoptosis in vitro . Transgenic mice expressing a subphysiological level of a p53 R172L minigene ( PB-p53 R172L ) in the prostate epithelium were generated and bred to the transgenic adenocarcinoma mouse prostate (TRAMP) model of prostate cancer. While PB-p53 R172L transgenic mice developed normally with no detectable prostate gland phenotype, we observed a significant increase in the apoptotic index in the prostate glands of TRAMP × PB-p53 R172L F1 mice. We noted an increase in the expression of Bax in the bigenic mice concomitant with the reduced incidence and rate of tumor growth and increased survival. While low-level expression of the p53 R172L variant had no obvious influence on normal prostate tissue, it was able to significantly inhibit prostate cancer progression in the context of a genetically predisposed model system. This suggests that additional tumor-related events specifically influence the ability of the variant p53 R172L molecule to inhibit tumor growth. These studies support gene therapy strategies employing specific p53 variants.
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    64
    References
    25
    Citations
    NaN
    KQI
    []